{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:09:41Z","timestamp":1782742181060,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bbmt.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:06:43Z","timestamp":1523970403000},"page":"1406-1414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Salyka","family":"Sengsayadeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mailhol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-7824","authenticated-orcid":false,"given":"Katie S.","family":"Gatwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.04.008_bib0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.beha.2006.10.006","article-title":"Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?","volume":"20","author":"Larson","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","article-title":"Reasons for treating secondary AML as de novo AML","volume":"85","author":"Ostgard","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0025","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0030","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V89.7.2578","article-title":"Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy","volume":"89","author":"Anderson","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0035","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/cncr.23325","article-title":"Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and\/or radiation","volume":"112","author":"Abdelhameed","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cancergencyto.2010.06.013","article-title":"Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML","volume":"202","author":"Preiss","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0045","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0055","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/asheducation-2007.1.453","article-title":"Etiology and management of therapy-related myeloid leukemia","volume":"2007","author":"Larson","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0065","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0070","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0075","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1200\/JCO.2005.05.202","article-title":"Treatment of secondary acute myeloid leukemia","volume":"23","author":"Pulsoni","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0085","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.24379","article-title":"Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia","volume":"115","author":"Rizzieri","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/leu.2010.279","article-title":"Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial","volume":"25","author":"Stolzel","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0095","doi-asserted-by":"crossref","first-page":"72044","DOI":"10.18632\/oncotarget.12495","article-title":"Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: a national population-based cohort study of Danish intensive chemotherapy patients","volume":"7","author":"Ostgard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.23605","article-title":"Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia","volume":"89","author":"Ornstein","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5045\/br.2013.48.3.185","article-title":"Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia","volume":"48","author":"Park","year":"2013","journal-title":"Blood Res"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0110","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.leukres.2013.04.016","article-title":"Prognosis of secondary acute myeloid leukemia","volume":"37","author":"Della Porta","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0115","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","article-title":"Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Josting","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/beha.2000.0119","article-title":"Biology and therapy of secondary leukaemias","volume":"14","author":"Dann","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0125","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0135","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Thanarajasingam","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0140","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/bmt.2014.116","article-title":"Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation","volume":"49","author":"Bejanyan","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0145","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0150","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","article-title":"Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Oran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0145-2126(00)00142-9","article-title":"Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation","volume":"25","author":"Lee","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0160","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0165","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0170","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00277-017-3027-5","article-title":"Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation","volume":"96","author":"Heuser","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0175","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/bmt.2015.59","article-title":"Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission","volume":"50","author":"Michelis","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0180","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.04.008_bib0185","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:51Z","timestamp":1761058971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118301897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1083879118301897"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}